Phase 3 trial

Oculis secures FDA agreement on Phase 3 trial design for Privosegtor optic neuritis treatment, de-risking regulatory pathway and clearing way for future drug submission.

Oculis secures FDA Special Protocol Assessment for Privosegtor Phase 3 trial, de-risking path to potential $7 billion optic neuritis market.

TScan Therapeutics reports $28.7M Q1 loss, $1.0M revenue; $128.1M cash funds operations to H2 2027 amid Phase 3 pipeline advancement.

Immunocore reports $106.7M Q1 KIMMTRAK sales, up 14% YoY, with landmark data showing doubled five-year survival in uveal melanoma patients.

Relmada to present NDV-01 Phase 2 data showing 76% response rate in bladder cancer at AUA 2026 conference; Phase 3 registration trial launches mid-2026.

FDA approves VEPPANU, first PROTAC therapy for advanced breast cancer with ESR1 mutations, showing 43% reduction in disease progression risk versus existing treatment.

Pharvaris director's modest 1.80% stock sale matters less than upcoming Phase 3 data and FDA submission catalysts arriving in 2026.

Pfizer's ELREXFIO cancer therapy shows superior efficacy in Phase 3 myeloma trial, but stock declines amid analyst skepticism about growth prospects.

Boehringer's survodutide shows 16.6% weight loss in Phase 3 trial, benefiting Zealand Pharma with EUR 315M in potential milestone payments and ongoing royalties.

Altimmune closed a $225M oversubscribed public offering led by Deep Track Capital. Proceeds will fund Phase 3 MASH trial initiation in H2 2026 and operational runway through data readout.

Relay Therapeutics reports positive Phase 2 data for zovegalisib triplet combination in metastatic breast cancer, planning Phase 3 launch in early 2027.

Altimmune raises $225M in oversubscribed offering to fund Phase 3 MASH trial, pricing 64.25M shares at $3.00 each.

Inventiva appoints three senior executives to strengthen leadership before Phase 3 lanifibranor data readout expected Q4 2026.

Inventiva appoints three new executives to strengthen leadership before anticipated Phase 3 lanifibranor trial results expected in Q4 2026.

Madrigal Pharmaceuticals reports Q1 2026 results May 6, revealing early commercial performance of FDA/EMA-approved MASH treatment Rezdiffra following recent regulatory clearances.

Ocular Therapeutix schedules June 17 investor day in NYC while reporting positive Week 52 data from SOL-1 Phase 3 trial of AXPAXLI for wet AMD treatment.

Dianthus Therapeutics CFO Ryan Savitz sold 8,224 shares for $739,000 on April 9, 2026, reducing direct holdings to zero while retaining substantial options.

Theriva Biologics will present expanded VIRAGE trial data for VCN-01 at AACR 2026, with FDA and EMA agreement on Phase 3 design for metastatic pancreatic cancer treatment.

Aicuris receives FDA Priority Review for pritelivir, a novel herpes simplex virus treatment. Phase 3 data shows 82.4% healing rate; PDUFA decision expected Q4 2026.

Revolution Medicines surges 40% after Phase 3 trial shows daraxonrasib doubles survival in metastatic pancreatic cancer versus chemotherapy.